Literature DB >> 16838117

Expression of transforming growth factor-alpha and -beta in hepatic lobes after hemihepatic portal vein embolization.

Koji Kusaka1, Hiroshi Imamura, Tomoaki Tomiya, Tadatoshi Takayama, Masatoshi Makuuchi.   

Abstract

Hemihepatic portal vein embolization (PVE) concomitantly induces atrophy in embolized and compensatory hypertrophy in nonembolized hepatic lobes. The aim of the present study was to evaluate the involvement of growth stimulatory and inhibitory factors in these hepatic lobes after PVE. Liver specimens from the embolized and nonembolized lobes of ten patients who underwent hepatectomy (8-22 days) after undergoing PVE were obtained. Proliferation and apoptosis were examined immunohistochemically using Ki-67 and the Tdt-mediated dUTP-biotin nick end-labeling method. The expression of transforming growth factor-alpha (TGF-alpha) and transforming growth factor-beta (TGF-beta) was also examined by immunohistochemical staining. PVE induced hepatocyte apoptosis in the embolized lobe and hepatocyte proliferation in the nonembolized lobe. TGF-alpha expression in the hepatocytes of the nonembolized lobe was markedly increased, whereas TGF-alpha was also overexpressed, albeit moderately, in the embolized lobe. In contrast, TGF-beta expression in the hepatocytes of the embolized lobe was significantly increased, and TGF-beta expression was also increased, although to a lesser extent, in the nonembolized lobe. The degree of volume changes of the nonembolized lobe and the embolized lobe after PVE was statistically correlated with the ratios of TGF-alpha and TGF-beta expression in these lobes (r = 0.886, P < .0001). In conclusion, these findings indicate that TGF-alpha and TGF-beta expression (assessed by immunohistochemical staining) increase in relation to hepatocyte proliferation and apoptosis, respectively, after PVE in humans and the balance of the two factors may contribute to hepatic atrophy and hypertrophy concomitantly observed in this model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16838117     DOI: 10.1007/s10620-006-9105-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  37 in total

1.  Expression of hepatocyte growth factor, transforming growth factor alpha, and transforming growth factor beta 1 messenger RNA in various human liver diseases and correlation with hepatocyte proliferation.

Authors:  M Masuhara; M Yasunaga; K Tanigawa; F Tamura; S Yamashita; I Sakaida; K Okita
Journal:  Hepatology       Date:  1996-08       Impact factor: 17.425

2.  Changes in levels of mRNAs of transforming growth factor (TGF)-beta1, -beta2, -beta3, TGF-beta type II receptor and sulfated glycoprotein-2 during apoptosis of mouse uterine epithelium.

Authors:  K Wada; S Nomura; E Morii; Y Kitamura; Y Nishizawa; A Miyake; N Terada
Journal:  J Steroid Biochem Mol Biol       Date:  1996-12       Impact factor: 4.292

3.  Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor.

Authors:  B I Carr; I Hayashi; E L Branum; H L Moses
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

4.  Choline deficiency causes increased localization of transforming growth factor-beta1 signaling proteins and apoptosis in the rat liver.

Authors:  C D Albright; S H Zeisel
Journal:  Pathobiology       Date:  1997       Impact factor: 4.342

5.  Transforming growth factor-beta (TGF-beta) isoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-beta.

Authors:  S B Jakowlew; J E Mead; D Danielpour; J Wu; A B Roberts; N Fausto
Journal:  Cell Regul       Date:  1991-07

6.  Fate of the human liver after hemihepatic portal vein embolization: cell kinetic and morphometric study.

Authors:  H Harada; H Imamura; S Miyagawa; S Kawasaki
Journal:  Hepatology       Date:  1997-11       Impact factor: 17.425

7.  Portal vein embolization before right hepatectomy: prospective clinical trial.

Authors:  Olivier Farges; Jacques Belghiti; Reza Kianmanesh; Jean Marc Regimbeau; Roberto Santoro; Valérie Vilgrain; Alban Denys; Alain Sauvanet
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

8.  Transforming growth factor beta (TGF-beta) inhibits hepatocyte DNA synthesis independently of EGF binding and EGF receptor autophosphorylation.

Authors:  W E Russell
Journal:  J Cell Physiol       Date:  1988-05       Impact factor: 6.384

9.  Transforming growth factor-alpha expression during liver regeneration after partial hepatectomy and toxic injury, and potential interactions between transforming growth factor-alpha and hepatocyte growth factor.

Authors:  E M Webber; M J FitzGerald; P I Brown; M H Bartlett; N Fausto
Journal:  Hepatology       Date:  1993-12       Impact factor: 17.425

10.  Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis.

Authors:  J W Fang; G L Bird; T Nakamura; G L Davis; J Y Lau
Journal:  Lancet       Date:  1994-04-02       Impact factor: 79.321

View more
  9 in total

Review 1.  Portal vein embolization before liver resection: a systematic review.

Authors:  K P van Lienden; J W van den Esschert; W de Graaf; S Bipat; J S Lameris; T M van Gulik; O M van Delden
Journal:  Cardiovasc Intervent Radiol       Date:  2012-07-18       Impact factor: 2.740

2.  Liver regeneration and the atrophy-hypertrophy complex.

Authors:  Robin D Kim; Jae Sung Kim; Go Watanabe; Dagmara Mohuczy; Kevin E Behrns
Journal:  Semin Intervent Radiol       Date:  2008-06       Impact factor: 1.513

3.  Can plasma bile salt, triglycerides, and apoA-V levels predict liver regeneration?

Authors:  Lisette T Hoekstra; Krijn P van Lienden; Frank G Schaap; Rob A F M Chamuleau; Roel J Bennink; Thomas M van Gulik
Journal:  World J Surg       Date:  2012-12       Impact factor: 3.352

4.  Increase in the serum bile acid level predicts the effective hypertrophy of the nonembolized hepatic lobe after right portal vein embolization.

Authors:  Hiromitsu Hayashi; Toru Beppu; Hiroki Sugita; Kei Horino; Hiroyuki Komori; Toshiro Masuda; Hirohisa Okabe; Hiroshi Takamori; Hideo Baba
Journal:  World J Surg       Date:  2009-09       Impact factor: 3.352

5.  Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case-control study.

Authors:  Rohan C Siriwardana; Chung Mau Lo; See Ching Chan; Sheung Tat Fan
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

6.  Liver atrophy after percutaneous transhepatic portal embolization occurs in two histological phases: Hepatocellular atrophy followed by apoptosis.

Authors:  Yasuhito Iwao; Hidenori Ojima; Tatsushi Kobayashi; Yoji Kishi; Satoshi Nara; Minoru Esaki; Kazuaki Shimada; Nobuyoshi Hiraoka; Minoru Tanabe; Yae Kanai
Journal:  World J Hepatol       Date:  2017-11-18

7.  Liver Resection After Selective Internal Radiation Therapy with Yttrium-90: Safety and Outcomes.

Authors:  Sebastian Mafeld; Peter Littler; Hannah Hayhurst; Derek Manas; Ralph Jackson; John Moir; Jeremy French
Journal:  J Gastrointest Cancer       Date:  2020-03

8.  Identification of crucial lncRNAs and mRNAs in liver regeneration after portal vein ligation through weighted gene correlation network analysis.

Authors:  Yan Zhu; Zhishuai Li; Jixiang Zhang; Mingqi Liu; Xiaoqing Jiang; Bin Li
Journal:  BMC Genomics       Date:  2022-09-21       Impact factor: 4.547

9.  Effect of portal vein embolisation on the growth rate of colorectal liver metastases.

Authors:  V Pamecha; A Levene; F Grillo; N Woodward; A Dhillon; B R Davidson
Journal:  Br J Cancer       Date:  2009-02-10       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.